21 June 2023 - The meeting was held on 16-17 February 2023 in person and via Zoom.

The PTAC considered applications for the following technologies:

• Ustekinumab for patients with Crohn's disease - recommended (low priority)
• Ustekinumab for patients with ulcerative colitis - recommended (low priority)
• Voretigene neparvovec for patients with an RPE65-mediated inherited retinal dystrophy - deferred
• Rotigotine for patients with Parkinson's disease  - recommended (if cost-neutral)
• Rotigotine for patients with restless legs syndrome - recommended (if cost-neutral)
• Ketamine for patients in palliative care with intractable pain - recommended (low priority)
• Darolutamide for patients with prostate cancer - recommended (high priority)
• Methylnaltrexone bromide for patients with opioid-induced constipation - recommended (low priority)
  

In summary, only two new medicines (one recommended, the other deferred) and just one cancer medicine (recommended).

Read PTAC minutes